Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;16(4):28-31.

Concomitance of Hidradenitis Suppurativa and Porokeratoses

Affiliations

Concomitance of Hidradenitis Suppurativa and Porokeratoses

Christopher J Sayed et al. J Clin Aesthet Dermatol. 2023 Apr.

Abstract

Objective: No known studies have attempted to describe the pathophysiological relationship between patients who develop both porokeratosis and hidradenitis suppurativa (HS). The purpose of this report is to present possible immunological mechanisms that predispose patients to developing both porokeratosis and HS.

Methods: In this case series, patients were identified during routine clinical encounters and data was extracted from the electronic medical record from October 2010 until April 2021. This study is a single center case series including patients from the department of dermatology at the UNC School of Medicine in Chapel Hill, North Carolina. Patients were selected via digital chart review if they had simultaneous diagnoses of disseminated porokeratosis and HS. Two eligible patients were identified as actively receiving care. One patient is a Black female and the other a White male. No primary study outcomes were planned. This investigation utilized chart review to identify disease time course, which was subsequently used to elucidate study outcomes.

Results: Patient A is a 54-year-old Black female and Patient B is a 65-year-old White male. Both patients developed porokeratosis after multiple years of living with HS. Immunosuppression with adalimumab, corticosteroids, or other medications did not clearly precede porokeratosis development in either patient.

Limitations: Limitations include that this study was conducted at a single center and prevalence of patients with concomitance of both conditions is low.

Conclusion: In patients who demonstrate simultaneous HS and porokeratosis, activation of the innate immune system and associated IL-1 production may lead to autoinflammation and a phenotype of hyperkeratinization. Mutations in genes such as mevalonate kinase may predispose subjects to the development of porokeratoses and HS.

Keywords: Hidradenitis suppurativa; interleukin-1 (IL-1); porokeratoses; porokeratosis.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURES: The authors report no conflicts on interest relevant to the content of this article.

Figures

FIGURE 1.
FIGURE 1.
Porokeratosis plantaris palmaris et disseminata; Scattered hyperpigmented, hyperkeratotic spiny papules and plaques are spread diffusely over the A) lower back; and B) left shoulder. Scattered hyperpigmented, hyperkeratotic papules, plaques, and scale are spread over the C) scalp and D) right palm.
FIGURE 2.
FIGURE 2.
Porokeratosis on the back and shoulders; Widespread, confluent, lichenified, and hyperpigmented plaques with excoriation on the A) shoulders and chest; and B) lower back.
FIGURE 3.
FIGURE 3.
Histologic presentation of HS and PPPD; A) Double comedones lead to a follicle cyst. Surrounding follicles have dilated canals. There are coronoid lamellae in multiple foci in the epidermis as well as in the dilated follicles (H&E 3X). B) The epidermis has hyperplasia with a column of parakeratosis emanating from a depression in the epidermis. Coronoid lamellae such as this were in the epidermis and follicles in multiple specimens from the patient (H&E 5X). C) A cystically dilated follicle has inspissated keratin and a tiny coronoid lamellae in the lower left of the image (H&E 20X). D) Follicular structures in the deep dermis showed cystic change and were surrounded by dense mixed inflammation with lymphocytes, macrophages, neutrophils and many eosinophils (H&E 13X).

References

    1. Chernosky ME. Porokeratosis. Arch Dermatol. 1986;122(8):869–870. - PubMed
    1. Alikhan A et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81(1):76–90. - PMC - PubMed
    1. Garg A Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. 2021. J Am Acad Dermatol. - PMC - PubMed
    1. Smith J et al. Brachytherapy for Resistant Disseminated Superficial Actinic Porokeratosis. Applied Radiation Oncology. 2020;9(3):p. 43–45.
    1. Young PM et al. An unusual spiculated presentation of follicular porokeratosis. Dermatol Online J. 2019;25(7) - PubMed

LinkOut - more resources